Royal College of General Practitioners and British Medical Association raise concerns about the roll out of inclisiran for primary hypercholesterolaemia in

Following the NICE TA approval, RCGP & BMA highlight lack of long term cardiovascular & safety data and capacity & resources issues are potential concerns for the proposed provision via primary care. They will continue to work with NHSEI to understand more about the proposals.

SPS commentary:

NICE TA733 recommends inclisiran as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults only if:

  • There is a history of any of the following cardiovascular events:
    • acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
    • coronary or other arterial revascularisation procedures
    • coronary heart disease
    • ischaemic stroke or
    • peripheral arterial disease

and

  • Low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is:
    • maximum tolerated statins with or without other lipid-lowering therapies or,
    • other lipid-lowering therapies when statins are not tolerated or are contraindicated,

Royal College of General Practitioners

Resource links:

NICE TA733